Patient-Based Therapeutics

AcuraStem is a patient-based biotechnology company pioneering how treatments are developed for neurodegenerative diseases — including sporadic ALS and FTD — using our proprietary, best-in-class, disease-modeling platform, iNeuroRx®, the gold standard for discovering novel, effective and broadly-acting treatments.

get to know us

Patient Focused

rp3.jpgrp1.jpgrp2.jpg

rp4.jpgThe main reason drugs fail in clinical trials is due to an over reliance on animal models, which leads to a poor understanding of the real human mechanisms driving disease. AcuraStem are leaders and inventors in the generation of individual patient models that accurately recapitulate neurodegenerative disease processes. This, what we call our patient-based approach, leads to more effective treatments, and treatments that can work broadly for patients, not limited to rare, genetically defined subtypes. 


learn about our work

Neurodegenerative Disease Areas

Latest News

April 28, 2026

CIRM Awards AcuraStem $7.5 Million in Grant Funding to Advance AS-241 Toward a First‑in‑Human Trial for ALS and FTD

PASADENA, Calif., April 28, 2026– AcuraStem, a biotechnology company advancing treatments for amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases, announced today that the California Institute for Regenerative Medicine (CIRM) has awarded the company $7.5 million in grant funding to support the advancement of its lead clinical candidate, AS-241, toward first‑in‑human testing.

» Read more
April 16, 2026

AcuraStem Expands Global Presence with European Subsidiary in Cyprus

PASADENA, Calif., April 16, 2026 – AcuraStem, a patient‑based biotechnology company advancing treatments for amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases, today announced the establishment of its European subsidiary, AcuraStem P2 Ltd, based in Nicosia, Cyprus.

» Read more
March 10, 2026

AcuraStem Awarded Target ALS Grant to Advance Therapeutics Targeting a Core Driver of ALS

PASADENA, Calif., March 10, 2026 — AcuraStem, a patient-based biotechnology company developing disease- modifying therapies for amyotrophic lateral sclerosis (ALS), today announced it has received a two-year research grant from Target ALS to advance therapeutics targeting SYF2, a recently identified regulator of TDP43 function. TDP-43 dysfunction is a central biological hallmark of ALS.

» Read more

Keep Up to Date with AcuraStem